Multicenter Phase I Clinical Trial
Also known as: multisite Phase I trial, multi-institutional Phase I study, Phase I dose-escalation multicenter study, first-in-human multicenter trial
A multicenter Phase I clinical trial is the first systematic administration of an investigational agent to humans, conducted simultaneously across two or more clinical sites. Its primary objectives are to characterize the safety and tolerability profile of the intervention, determine the maximum tolerated dose (MTD), and describe pharmacokinetic and pharmacodynamic behavior. Distributing enrollment across sites increases participant accrual speed and enhances the generalizability of early-phase safety data.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Use a multicenter Phase I design when the target patient population is rare or geographically dispersed, making enrollment at a single site impractically slow. It is also preferred when regulatory authorities or sponsors require early-phase data that reflects geographic or demographic diversity, or when the sponsoring institution lacks sufficient specialist infrastructure (e.g., dose-escalation units, pharmacokinetic laboratories). Do not use this design when a single-site Phase I is feasible and sufficient — multicenter Phase I trials introduce substantial coordination overhead, higher costs, and risks of protocol drift. If the available patient population at one expert center can meet enrollment targets within an acceptable timeframe, a single-site Phase I is simpler and easier to control.
Strengths & limitations
- Faster participant accrual than single-site studies, which is critical for rare-disease or narrow-eligibility first-in-human trials.
- Safety signals observed across diverse sites and patient populations increase confidence that toxicity findings are generalizable rather than site-specific.
- Supports regulatory submissions that require evidence of safety in demographically diverse populations.
- Allows sponsors to build investigator networks early, facilitating smoother transition to multicenter Phase II and III trials.
- Central pharmacokinetic analysis reduces assay variability relative to site-level analysis.
- Substantial coordination overhead: protocol harmonization, cross-site training, and central monitoring increase cost and complexity significantly.
- Protocol drift across sites can introduce heterogeneity in dose-escalation decisions and adverse event grading despite harmonization efforts.
- Ethics committee and regulatory approvals must be obtained independently at each site, prolonging the startup timeline.
- Central pooling of DLT data for escalation decisions requires robust real-time data systems and rapid inter-site communication.
- Attribution of site-level differences in tolerability to true pharmacological variability versus local practice variation can be difficult.
Frequently asked
What is the main difference between a single-site and a multicenter Phase I trial?
The core methodology — dose escalation, DLT assessment, PK sampling — is identical. The critical differences are operational: multicenter trials require a coordinating center, harmonized protocols across all sites, a centralized DSMB that reviews pooled safety data before each escalation decision, and central laboratory analysis for pharmacokinetics. Multicenter trials enroll faster but are more costly and complex to manage.
How are dose-escalation decisions made when participants are enrolled at multiple sites simultaneously?
Escalation decisions must be based on pooled data from all sites, not site-by-site data. The data safety monitoring board or escalation committee waits until the complete DLT observation window has elapsed for all participants in the current cohort across all sites, then reviews the combined DLT count before authorizing escalation or declaring the MTD. Individual sites must not escalate independently.
Does a multicenter Phase I trial require a single IND or multiple INDs?
In the United States, a single Investigational New Drug (IND) application covers all sites; the sponsor holds the IND and is responsible for all sites. Internationally, country-specific regulatory filings (e.g., CTA in Europe) are required at each national regulatory authority, even when the protocol is identical — this is one of the major startup-time challenges in multinational multicenter Phase I trials.
Can pharmacokinetic sampling be performed at all sites, or should it be centralized?
Sampling can occur at all sites — it must, since participants are dosed at their local site. However, sample processing and bioanalytical assays should be performed at a single central laboratory whenever logistically feasible. This eliminates inter-laboratory assay variability and ensures that PK parameters computed from different participants' samples are directly comparable.
When is a multicenter Phase I design not appropriate?
When a single expert center can enroll the required number of participants within the planned timeframe, a single-site Phase I is preferable — it is simpler to manage, less costly, and less prone to protocol drift. Multicenter Phase I is also not appropriate as a substitute for a well-designed Phase II efficacy study: if the scientific question is primarily about efficacy rather than safety and MTD, a Phase II design with appropriate statistical power is required.
Sources
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). ICH. link ↗
- Storer, B. E. (1989). Design and analysis of Phase I clinical trials. Biometrics, 45(3), 925-937. DOI: 10.2307/2531693 ↗
How to cite this page
ScholarGate. (2026, June 3). Multicenter Phase I Clinical Trial. ScholarGate. https://scholargate.app/en/epidemiology/multicenter-phase-i-clinical-trial
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Adaptive Phase I Clinical TrialEpidemiology↔ compare
- Bayesian Phase I clinical trialEpidemiology↔ compare
- Dose-Response AnalysisEpidemiology↔ compare
- Multicenter Randomized Clinical TrialEpidemiology↔ compare
- Phase I Clinical TrialEpidemiology↔ compare
- Phase II clinical trialEpidemiology↔ compare